Please login to the form below

Not currently logged in
Email:
Password:

Avandia wins FDA reprieve

The FDA's advisory votes 22 to 1 in favour to keep GSK's troubled diabetes drug Avandia on the US market

The FDA's advisory committee has voted 22 to 1 in favour to keep UK-headquartered GlaxoSmithKline's (GSK) troubled diabetes drug Avandia (roseglitazone) on the US market.

On 30 July, GSK presented new data to Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee.

They voted that the data suggests some ischemic risk with Avandia, a treatment for type 2 diabetes. The committee declined to comment on comparative risk of Avandia with other oral anti-diabetic medicines, but nevertheless voted to keep the medicine available to patients in the US. The FDA will review the panel's recommendation before making a final decision.

"This was the first opportunity for these scientific experts to review the full data behind Avandia. The committee recognized the debilitating nature of this disease and the importance of multiple treatment options," said Dr Ronald Krall, GSKís CMO.

Concerns over Avandia were first raised in May 2007, when the New England Journal of Medicine (NEJM) published research claiming the treatment could increase the risk of heart attacks.

In the EU, both the European Medicines Agency (EMEA) and the UK's Medicines Healthcare Regulatory Agency (MHRA) are re-evaluating the drug's benefits in light of possible links with heart failure.

GSK has maintained its forecast for FY07 earnings per share growth of eight to 10 per cent following the panel's decision.

31st July 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...
Deal Watch January 2018
...
Emotional Intelligence and Blended Learning in Healthcare
EI and emotional selling are rising up the agenda when it comes to healthcare training. This article outlines how blended learning approaches can help put them into action....

Infographics